Nektar Therapeutics (NKTR) Other Operating Expenses (2010 - 2025)

Nektar Therapeutics' Other Operating Expenses history runs 16 years deep, the most recent figure standing at -$43.3 million for Q2 2025.

• On a quarterly basis, Other Operating Expenses rose 3.12% year-over-year to -$43.3 million in Q2 2025; TTM through Mar 2026 was -$43.3 million, a 87.36% increase from a year earlier, with the FY2024 full-year figure at -$175.9 million, down 13432.46% from the prior year.
• Other Operating Expenses improved to -$43.3 million in Q2 2025 per NKTR's latest filing, from -$50.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $103.2 million in Q1 2023 and bottomed at -$198.6 million in Q4 2024.
• The 5-year median for Other Operating Expenses is $5.3 million (2021), against an average of -$18.6 million.
• Biggest YoY gain for Other Operating Expenses was 1840.85% in 2023; the steepest drop was 2556.73% in 2023.
• Year by year, Other Operating Expenses stood at $6.2 million in 2021, then advanced by 1.14% to $6.2 million in 2022, then plunged by 2556.73% to -$153.1 million in 2023, then slipped by 29.72% to -$198.6 million in 2024, then soared by 78.21% to -$43.3 million in 2025.
• Per Business Quant, the three latest NKTR Other Operating Expenses figures stand at -$43.3 million (Q2 2025), -$50.5 million (Q1 2025), and -$198.6 million (Q4 2024).